Abstract: A subject is prescribed short and long acting insulin medicament regimens. When a qualified fasting event occurs, the basal insulin sensitivity estimate of the subject is updated using (i) an expected fasting blood glucose level based upon the long acting insulin medicament dosing specified by the long acting regimen during the fasting event, (ii) glucose measurements contemporaneous with the fasting event and (iii) a prior insulin sensitivity factor. A basal insulin sensitivity factor curve is calculated from the updated basal insulin sensitivity estimate. A bolus insulin sensitivity estimate of the subject is updated upon occurrence of a correction bolus with a short acting insulin medicament using (i) an expected blood glucose level based upon the correction bolus, (ii) glucose measurements after occurrence of the correction bolus, and (iii) a prior insulin sensitivity factor. A bolus insulin sensitivity factor curve is calculated from the updated bolus insulin sensitivity estimate.

Abstract: The present invention provides a solution for zero-point adjustment of drug delivery devices, including twin chamber drug delivery devices with a single dose engine.

Abstract: This invention relates to glucose-sensitive albumin-binding diboron conjugates. More particularly the invention provides novel diboron compounds, and in particular diboronate or diboroxole compounds, useful as intermediate compounds for the synthesis of diboron conjugates. The diboron compounds are characterized by formula (I), which is: R1-X—R2, and wherein “X” is a mono- to multiatomic linker and where R1 and R2, which may be identical or different, each represents a group of Formula (11a) or (IIb) Also described are diboron conjugates represented by the general Formula (I?), which is: R1?-X?—R2?, in which either the moeities R1? or R2? or X? carry a drug that is covalently attached to the diboron compound.

Abstract: Articles for rapid release of components including, for example, quick release capsules, are generally provided. Advantageously, in some embodiments, the articles described herein may be configured to prevent fluid from contacting a component h contained therein (e.g., tissue interfacing component) or payload contained therein until a desired time, e.g., the time at which the component is configured to release from the article to a location internal to a subject (e.g., localize to a tissue wall in the subject). In some embodiments, the article comprises a first compartment and a second compartment not in fluid communication with the first compartment. In some embodiments, the first compartment and second compartment are fluidically isolated. For example, in some cases, the first compartment comprises a mechanism for releasing a component contained within the article and the second compartment comprises the component.

Abstract: Drug delivery device adapted to expel a set dose, comprising an expelling mechanism with a drive spring, a dose setting mechanism with first and second dose setting ratchet parts, a bias spring as well as control means. The control means is adapted to rotate the second ratchet part in a first direction to thereby set a dose when rotating the dose setting member in the first direction, and move the ratchet parts axially out of engagement with each other when the dose setting member is rotated in the opposite direction. When the first and second ratchet parts have been axially disengaged, the drive spring will rotate the second ratchet part in the second direction to thereby reduce the set dose, the bias spring moving the ratchet parts axially into engagement with each other again, this resulting in the set dose being reduced corresponding to one tooth of the ratchet mechanism.

Abstract: The present invention relates to solid compositions for oral administration comprising (i) a GLP-1 derivative and the SGLT2 inhibitor dapagliflozin or (ii) a GLP-1 derivative and a salt of NAC in combination with an SGLT2 inhibitor.

Abstract: The invention is related to insulin compositions with a high content of zinc atoms per six molecules of acylated insulin. The insulin is an acylated insulin and may be mixed with a further insulin analogue such as the rapid acting insulin Asp B28 human insulin.

Abstract: A portable pen-type drug injection device (300) comprises a main portion (301) and a clip (360). The clip comprises a base portion mounted to a portion of the drug delivery device, and a clip gripping portion with a free end. The device further comprises drug expelling means having dose setting means (340) allowing a user to set a dose of drug to be expelled, and a piston rod adapted to move a piston of a loaded cartridge in a distal direction to thereby expel drug from the cartridge. Electronic circuitry comprises sensor means adapted to detect a set and/or an expelled dose, and a display (374) is provided to display dose-related values, wherein at least a portion of the display is arranged in the flexible clip main portion.

Abstract: The disclosure provides apolipoprotein C-II (apoC-II) mimetic peptides and methods for treating hypertriglyceridemia in a patient with an effective amount of an apoC-II mimetic peptide.

Abstract: The application discloses compounds useful in treatment of diabetes, weight loss and/or reduction of cardiovascular risks. The compounds are bi-functional and therefore suitable as a simple treatment for patients that may benefit from treatment with both a GLP-1 receptor agonist and a PCSK9 inhibitor.

Abstract: The invention relates to granules and pharmaceutical compositions comprising a salt of N-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant obtained by mixing hereof for more than 5 minutes prior to granulation as well as processes for their preparation and use thereof in medicine.

Abstract: Systems and methods are provided for optimizing basal administration timing in a standing basal insulin regimen of a subject. The regimen specifies a total amount of basal insulin medicament, one or more basal injection event types for a recurring period, and an apportionment of the total amount of medicament between the injection event types. Time stamped glucose measurements of the subject are obtained over a past time course comprising a plurality of instances of the recurring period. When the glucose measurements satisfy a stop condition, a recommended adjustment is determined that comprises a change in the number of injection event types in the regimen and/or a change in the apportionment of insulin medicament between injection event types. The recommended adjustment is communicated to the subject for manual adjustment of the regimen, an insulin pen charged with delivering the regimen to the subject, or a health care practitioner associated with the subject.

Abstract: Drug delivery device adapted to expel a set dose, comprising an expelling mechanism with a drive spring, a dose setting mechanism with first and second dose setting ratchet parts, a bias spring as well as control means. The control means is adapted to rotate the second ratchet part in a first direction to thereby set a dose when rotating the dose setting member in the first direction, and move the ratchet parts axially out of engagement with each other when the dose setting member is rotated in the opposite direction. When the first and second ratchet parts have been axially disengaged, the drive spring will rotate the second ratchet part in the second direction to thereby reduce the set dose, the bias spring moving the ratchet parts axially into engagement with each other again, this resulting in the set dose being reduced corresponding to one tooth of the ratchet mechanism.

Abstract: The present invention relates to a drug delivery device that houses a piston equipped cartridge and a drive mechanism comprising a piston rod (170) configured for axially moving the piston in a distal direction. An adjustment member (150) connects to the member (150) comprises a first contour system (175) defining a plurality of steps (175?, 175?, 175??) being circumferentially disposed and arranged axially offset from one another. The other of the piston rod (170) and the adjustment member (150) comprises at least one radially disposed protrusion (155). For eliminating an axial clearance between the piston rod (170) and the piston of the cartridge the at least one radially disposed protrusion (155) axially engages a selective one of said plurality of steps (175?, 175?, 175??) so that the relative rotational position between the piston rod (170) and the adjustment member (150) is decisive for the axial position of the adjustment member (150) relative to the piston rod (170).

Abstract: The invention relates to a derivative of a GLP-1 analogue, which analogue comprises a first K residue at a position corresponding to position 27 of GLP-1(7-37) (SEQ ID NO: 1); a second K residue at a position corresponding to position T of GLP-1(7-37), where T is an integer in the range of 7-37 except 18 and 27; and a maximum of ten amino acid changes as compared to GLP-1(7-37); wherein the first K residue is designated K27, and the second K residue is designated KT; which derivative comprises two albumin binding moieties attached to K27 and KT, respectively, via a linker, wherein the albumin binding moiety comprises a protracting moiety selected from HOOC—(CH2)x—CO— and HOOC—C6H4—O—(CH2)y—CO—; in which x is an integer in the range of 6-16, and y is an integer in the range of 3-17; wherein the linker comprises an element of the formula —NH—(CH2)2—(O—(CH2)2)k—O—(CH2)n—CO—, wherein k is an integer in the range of 1-5, and n is an integer in the range of 1-5; or a pharmaceutically acceptable salt, amide, or este

Abstract: Systems and methods for communicating a dose history configured for representing an average and a variability of a distribution of injections with a blood glucose regulating medicament applied by a subject with a treatment regimen. Past records are obtained from insulin pens applying the treatment regimen. Each record specifies an amount and type of medicament injected, the type being one of a blood glucose regulating medicament, and a timestamp. Assigning single-shape polygons (231) to each record, wherein single-shape polygons (231) is configured for visualizing a polygon (261) with a two-dimensional shape, in a displayed mode. The single-shape polygons are used to create a set of multi-shape data structures comprising corresponding multi-shape polygons (244), configured for visualizing a polygon (265) with a two-dimensional shape, in the displayed mode (260).

Abstract: The present invention relates to the newly identified MIC-1 binding receptor, GFRAL. In vitro bioassays, for testing affinity and potency of GFRAL ligand, such as MIC- or MIC-1 variants, are provided.

Abstract: A drug delivery device adapted to receive a cartridge and hold it in a mounted position is provided, comprising a housing, an expelling assembly, and a front-loaded cartridge holder assembly adapted to receive and hold a cartridge in a mounted state. The assembly comprises cartridge holding means actuatable between a receiving state and a holding state, as well as a user operated actuation sleeve being rotationally actuatable relative to the housing between a loading state and an operational state, such that the cartridge holding means is actuated from the receiving state to the holding state when the actuation sleeve is actuated from the loading state to the operational state. The actuation sleeve is configured to enclose at least a portion of a mounted cartridge and is provided with inspection means allowing at least a portion of an enclosed cartridge portion to be visually inspected.

Abstract: The invention relates to an injection device for injecting a liquid drug. The injection device comprises a housing assembly supporting a non-removable cartridge having an interior chamber containing the liquid drug to be injected and a reusable needle cannula connected to the cartridge. A needle shield assembly provided with a cleaning chamber containing a volume of a cleaning agent for cleaning at least the distal tip of the needle cannula between subsequent injections is further provided.

Abstract: A syringe device for ejecting a dose of a medicament, the syringe device comprising: a dose limiting mechanism arranged to interact with a dose ejecting mechanism to prevent ejection of a dose exceeding a set dose, and a safety mechanism, which is arranged such with respect to the dose ejecting mechanism that, if the dose limiting mechanism fails, the safety mechanism prevents ejection of a dose exceeding the set dose.